• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The protective effects of MSC-EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway.
Abstract The aim of the study was to explore the mechanism of mesenchymal stem cell-derived exosomes (MSC-EXO) to protect against experimentally induced pulmonary hypertension (PH). Monocrotaline (MCT)-induced rat model of PH was successfully established by a single intraperitoneal injection of 50 mg/kg MCT, 3 weeks later the animals were treated with MSC-EXO via tail vein injection. Post-operation, our results showed that MSC-EXO could significantly reduce right ventricular systolic pressure (RVSP) and the right ventricular hypertrophy index, attenuate pulmonary vascular remodelling and lung fibrosis in vivo. I...
Source: J Cell Mol Med - October 22, 2020 Category: Molecular Biology Authors: Zhang Z, Ge L, Zhang S, Wang J, Jiang W, Xin Q, Luan Y Tags: J Cell Mol Med Source Type: research

Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells
Conclusion: In conclusion, increased VEGF-A produced by MSC can account for the increased vessel formation observed during treprostinil treatment. Moreover, our results suggest that VEGF-A level in patients could be a surrogate biomarker of treprostinil efficacy.
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Smadja, D., Levy, M., Huang, L., Rossi, E., Israel-Biet, D., Gaussem, P., Bischoff, J. Tags: 4.3 Pulmonary Circulation and Pulmonary Vascular Disease Source Type: research

Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells.
In conclusion, increased VEGF-A produced by MSC can account for the increased vessel formation observed during treprostinil treatment. The clinical relevance of these data was confirmed by the high level of VEGF-A detected in plasma from patients with paediatric PH who had been treated with treprostinil. Moreover, our results suggest that VEGF-A level in patients could be a surrogate biomarker of treprostinil efficacy. PMID: 26062754 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 11, 2015 Category: Hematology Authors: Smadja DM, Levy M, Huang L, Rossi E, Blandinieres A, Israël-Biet D, Gaussem P, Bischoff J Tags: Thromb Haemost Source Type: research